Compositions for treatment of heart failure in dogs
The invention relates to a new fixed dose combination of benazepril with pimobendan.
1. A bilayer tablet comprising a benazepril layer and a pimobendan layer,
wherein said benazepril layer comprises 50 mg of benazepril pellets, 35.06 mg microcrystalline cellulose, 26.76 mg sucrose, 1.72 mg crospovidone, 0.31 mg silica, colloidal anhydrous, and 1.15 mg magnesium stearate;
wherein said benazepril pellets comprise 5 wt % benazepril hydrochloride, microcrystalline cellulose, povidone, butyl methacrylate-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer, silicon dioxide, anhydrous, sodium lauryl sulfate, dibutyl sebacate, and silica, colloidal anhydrous; and
wherein said pimobendan layer comprises 1.25 mg pimobendan, 15 mg succinic acid, 2.5 mg polysorbate 80, 6.25 mg hypromellose, 15 mg maize starch, 140.325 mg lactose monohydrate, 15 mg starch pregelantinized, 3.75 mg croscarmellose sodium, 0.5 mg iron oxide brown, 6.25 mg copovidone, 8 mg flavorant, 1.075 mg silica, colloidal anhydrous, and 2.6 mg magnesium stearate.
2. A bilayer tablet comprising a benazepril layer and a pimobendan layer,
wherein said benazepril layer comprises 200 mg of benazepril pellets, 140.24 mg microcrystalline cellulose, 107.04 mg sucrose, 6.88 mg crospovidone, 1.24 mg silica, colloidal anhydrous, and 4.6 mg magnesium stearate;
wherein said benazepril pellets comprise 5 wt % benazepril hydrochloride, microcrystalline cellulose, povidone, butyl methacrylate-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer, silicon dioxide, anhydrous, sodium lauryl sulfate, dibutyl sebacate, and silica, colloidal anhydrous; and
wherein said pimobendan layer comprises 5 mg pimobendan, 60 mg succinic acid, 10 mg polysorbate 80, 25 mg hypromellose, 60 mg maize starch, 561.3 mg lactose monohydrate, 60 mg starch pregelantinized, 15 mg croscarmellose sodium, 2 mg iron oxide brown, 25 mg copovidone, 32 mg flavorant, 4.3 mg silica, colloidal anhydrous, and 10.4 mg magnesium stearate.